Helix BioPharma Corp. to Present at the Fourteenth World Conference on Lung Cancer in Amsterdam on July 5th, 2011

Helix BioPharma Corp. (TSX: HBP) (NYSE Amex: HBP) (FRANKFURT: HBP), a developer
of biopharmaceutical drug candidates for the prevention and treatment of cancer,
today announced that Heman Chao, Ph.D., Chief Scientific Officer, will be
presenting at the Fourteenth World Conference on Lung Cancer on July 5, 2011 at
the Amsterdam RAI Exhibition and Convention Centre, Netherlands.


Dr. Chao will conduct a poster presentation from 12:15PM - 14:00PM CEST (Central
European Summer Time). The poster will include some of the preclinical work
leading up to the recent United States Food and Drug Administration ("FDA")
approval of a Phase I investigational new drug ("IND") application to commence
human clinical testing. It will also highlight recent animal work in
31P-Magnetic Resonance Spectroscopy ("MRS") imaging and in vivo tumor pH
measurement. The poster will be available on Helix BioPharma's website
(www.helixbiopharma.com).


Additional information about the conference, provided by the organizers, can be
found at the conference's website http://www.2011worldlungcancer.org/index.html.


About L-DOS47

L-DOS47 is the Company's first drug candidate under development based upon its
DOS47 technology. L-DOS47 is a therapeutic immunoconjugate which combines
Helix's proprietary DOS47 technology with a highly specialized camelid-derived
single domain antibody designed to identify a unique CEACAM6 antigenic site
predominantly associated with non-small cell lung cancer ("NSCLC") cells. DOS47
is designed to function by leveraging a natural process in the body called the
urea cycle, to produce an anti-cancer effect. It is based upon a naturally
occurring enzyme called urease that essentially reverses the urea cycle by
breaking down urea into metabolites that include ammonia and hydroxyl ions. By
breaking down urea at the site of cancerous tissues in the body, L-DOS47 is
believed to modify the microenvironmental conditions of cancer cells in a manner
that leads to their death. Among these theorized effects, L-DOS47 is believed to
stimulate an increase in the pH of the microenvironment surrounding the
cancerous cells, effectively reversing the acidic extra-cellular conditions that
are known to be necessary for cancer cell survival. As well, the local
production of ammonia at the site of cancerous tissues is thought to readily
diffuse into the cancer cells to exert a potent cytotoxic effect by interfering
with their critical metabolic functions.


About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company focused on cancer therapy.
The Company is actively developing innovative products for the prevention and
treatment of cancer based on its proprietary technologies. Helix's product
development initiatives include its Topical Interferon Alpha-2b and its novel
L-DOS47 new drug candidate. Helix is listed on the TSX, NYSE Amex and FSE under
the symbol "HBP". For more information, please visit www.helixbiopharma.com.


Forward-Looking Statements and Risks and Uncertainties 

This News Release contains certain forward-looking statements and information
(collectively, "forward-looking statements"), regarding the Company's planned
presentation at the Fourteenth World Conference on Lung Cancer being held at the
Amsterdam RAI Exhibition and Convention Centre, Netherlands, and the Company's
product development initiatives. Although Helix believes that the expectations
reflected in such forward-looking statements are reasonable, such statements
involve risks and uncertainties, and undue reliance should not be placed on such
statements. Certain material factors or assumptions which have been applied in
making forward-looking statements, include, but are not limited to, assumptions
regarding the Company's attendance at the conference; the safety and efficacy of
Helix's drug candidates; the timely receipt of necessary regulatory approvals
and appropriate financing; and that the Company's drug candidates will
ultimately be successfully developed and commercialized. These forward-looking
statements are subject to risks and uncertainties that may cause actual events
or results to differ materially from such statements. These risks and
uncertainties include without limitation, that the Company's assumptions may
prove to be incorrect; that the presentation is subject to change or
cancellation without notice; Helix's need for additional future capital, which
may not be available; uncertainty whether the drug candidates will be
successfully developed and commercialized; research and development risks,
including manufacturing risks and negative clinical trial results; product
liability and insurance risks; the need for further regulatory approvals, which
may not be obtained in a timely matter or at all; intellectual property risks;
and uncertainty of the size and existence of a market opportunity for Helix's
products. These and other risks and uncertainties, which could cause actual
results to vary materially from current results or those anticipated in
forward-looking statements, are more fully described in our latest Form 20-F and
other documents filed on SEDAR at www.sedar.com and on EDGAR at ww.sec.gov. The
Company assumes no obligation, except as required by law, to update any
forward-looking statement, whether as a result of new information, future events
or otherwise.